Literature DB >> 30732965

Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases.

Eun-Jae Chung1, Woo-Jin Jeong1, Young Ho Jung1, Seong Keun Kwon1, Tack-Kyun Kwon1, Soon-Hyun Ahn2, Myung-Whun Sung1, Bhumsuk Keam3, Dae-Seog Heo3, Jin Ho Kim4, Hong-Gyun Wu4, Keun-Wook Lee5, Keun-Yong Eom6, Young-Soo Rho7.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the treatment outcomes for stage III/IV locally advanced hypopharyngeal squamous cell carcinoma (SCC), comparing induction chemotherapy followed by (chemo)radiotherapy (ICT), definitive chemoradiotherapy (CRT) and surgery-based therapy (SRT). SUBJECTS AND METHODS: Two hundred sixty-six patients with stage III/IV locally advanced hypopharyngeal squamous cell carcinoma (SCC) who underwent ICT (n = 74), CRT (n = 53) or SRT (n = 139) from 1997 through 2014 at the Seoul National University Hospital (n = 127) and the Hallym University Medical Center (n = 139) were enrolled in the study. All surgical procedures in the SRT group were performed by a single surgeon to eliminate surgeon bias.
RESULTS: The 5-year disease-free survival (DFS) and overall survival (OS) of all patients (n = 266) were 59.4% and 44%, respectively. The 5-year DFS rates after salvage treatment were 52.7% for ICT, 52.8% for CRT and 65.5% for SRT (p = 0.194). The OS rates were 44.6% for ICT, 39.6% for CRT and 45.3% for SRT group (p = 0.106). The salvage rates were 12.5% for ICT, 15.6% for CRT and 3.8% for SRT group. The final laryngeal preservation rate was significantly lower in the SRT group (44.6%) than in the ICT (71.6%) or CRT (71.7%) groups. All major postoperative complications were significantly higher in the salvage surgery group.
CONCLUSION: Treatment outcomes in the ICT and CRT groups were comparable to that of the SRT group for stage III/IV hypopharyngeal SCC. However, the relatively low chance of cure and high risk of complications should be taken into account when considering salvage surgery.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Hypopharyngeal cancer; Prognosis; Radiation therapy; Surgery

Mesh:

Year:  2018        PMID: 30732965     DOI: 10.1016/j.oraloncology.2018.12.015

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer.

Authors:  Jialing Wu; Kaiyun You; Changlong Chen; Huimin Zhong; Yanhui Jiang; Huaqian Mo; Juanjuan Song; Xingsheng Qiu; Yimin Liu
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

2.  Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensity-modulated radiotherapy.

Authors:  Dongqing Wang; Shui Yu; Limin Zhai; Jin Xu; Baosheng Li
Journal:  BMC Cancer       Date:  2020-04-06       Impact factor: 4.430

3.  Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.

Authors:  Xin Tian; Ying Xuan; Rong Wu; Song Gao
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

Review 4.  The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality.

Authors:  Daris Ferrari; Maria Grazia Ghi; Ciro Franzese; Carla Codecà; Max Gau; Jerome Fayette
Journal:  Front Oncol       Date:  2020-01-23       Impact factor: 6.244

5.  Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation.

Authors:  Xuecen Wang; Zhirui Cao; Xin Yue; Tingyu Liu; Gesi Wen; Dongmei Jiang; Weijian Wu; Liyuan Le; Yan Wang; Chengtao Wang; Ziyang Wang; Meng Jin; Meiyan Zhu; Shasha He; Xiaoyue Zhang; Xianzhang Bu; Ran-Yi Liu; Zhenwei Peng; Yong Chen
Journal:  Mol Ther Oncolytics       Date:  2022-08-05       Impact factor: 6.311

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.